New hope for tough liver cancer cases
NCT ID NCT05622071
Summary
This study tested a drug called tislelizumab for people with advanced liver cancer (hepatocellular carcinoma) who also had moderately weakened liver function (Child-Pugh B). The goal was to see if the drug, given alone, could effectively shrink tumors and control the cancer in this specific patient group. It involved 50 patients in France who received the drug by IV every three weeks for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA BY BCLC STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Strasbourg
Strasbourg, France
-
CHU Angers
Angers, France
-
CHU Beaujon
Clichy, France
-
CHU La Croix Rousse
Lyon, France
-
CHU Saint Eloi
Montpellier, France
-
Centre Eugene Marquis
Rennes, France
-
Hôpital Avicenne
Bobigny, France
-
Hôpital Michallon
Grenoble, France
-
Hôpital Saint Joseph
Marseille, France
-
Institut Paoli Calmette
Marseille, France
Conditions
Explore the condition pages connected to this study.